Agents In Management Research Articles

Multi-agent based energy community cost optimization considering high electric vehicles penetration

This paper proposes a multi-agent based solution to minimize the energy cost of an energy community, in day-ahead, that includes high penetration of electric vehicles. The proposed approach employs a structure of agents, including a central coordinator and energy management agents. To minimize the energy cost and to optimize the energy balance of the energy community, the proposed approach considers the energy demand and supply (i.e., photovoltaic generation), the battery storage systems’ charge and discharge actions, and the charging and discharging schedules of electric vehicles, including the possibility of vehicles to charge and discharge energy in public charging stations. The optimization problem is formulated as a mixed-integer linear programming problem, which is solved by an open-source solver and compared with the use of a commercial solver. The simulation results show that the proposed day-ahead approach can significantly reduce the cost of the energy community while ensuring a reliable and stable operation. Comparing the proposed solution with a centralized implementation, it is possible to significantly reduce the optimization time from hours to few seconds. Overall, the proposed multi-agent based solution provides a promising solution for the optimization of energy communities with high penetration of electric vehicles.

COMPARATIVE EVALUATION OF THE EFFECTS OF DEXMEDETOMIDINE-PROPOFOL AND FENTANYL-PROPOFOL ON VARIOUS PARAMETERS DURING I-GEL INSERTION

Objectives: Supraglottic airway devices (SGAD) have become inevitable for routine and difficult airway management and various induction agents are used for SGAD insertion. The present study compares the insertion conditions for I-gel, using Dexmedetomidine and Fentanyl with Propofol. Methods: Sixty patients were included in the study and randomly divided into two groups. Group D received 1 mcg/kg Dexmedetomidine and Group F received 1 mcg/kg Fentanyl. The mean arterial blood pressure (MAP) and heart rate (HR) were recorded at baseline and after 1’, 3’ 5’, and 10’ after insertion. Results: A significant decrease in HR was seen in Group D at 3’, 5’, and 10’ after insertion when compared to its respective time intervals in Group F. However, when MAP was observed, the 5’ after insertion showed a decrease in blood pressure within the groups but when MAP between groups were compared, there was no significant variation between Group F and Group D at their respective time intervals after insertion. HR was significantly reduced with Dexmedetomidine compared to that with Fentanyl. Conclusion: Co-induction of Propofol with Fentanyl or Dexmedetomidine 1 mcg/kg provides satisfactory hemodynamic stability and comparable insertion condition for I-Gel.

24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPARγ

Alcohol-related liver disease (ALD) is a global healthcare challenge with limited treatment options. 24-Norursodeoxycholic acid (NorUDCA) is a synthetic bile acid with anti-inflammatory properties in experimental and human cholestatic liver diseases. In the present study, we explored the efficacy of norUDCA in experimental ALD. NorUDCA was tested in a preventive and therapeutic setting in an experimental ALD model (Lieber-DeCarli diet enriched with ethanol). Liver disease was phenotypically evaluated using histology and biochemical methods, and anti-inflammatory properties and peroxisome proliferator-activated receptor gamma activation by norUDCA were evaluated in cellular model systems. NorUDCA administration ameliorated ethanol-induced liver injury, reduced hepatocyte death, and reduced the expression of hepatic pro-inflammatory cytokines including tumour necrosis factor (Tnf), Il-1β, Il-6, and Il-10. NorUDCA shifted hepatic macrophages towards an anti-inflammatory M2 phenotype. Further, norUDCA administration altered the composition of the intestinal microbiota, specifically increasing the abundance of Roseburia, Enterobacteriaceae, and Clostridum spp. In atherapeutic model, norUDCA also ameliorated ethanol-induced liver injury. Moreover, norUDCA suppressed lipopolysaccharide-induced IL-6 expression in human peripheral blood mononuclear cells and evoked peroxisome proliferator-activated receptor gamma activation. NorUDCA ameliorated experimental ALD, protected against hepatic inflammation, and affected gut microbial commensalism. NorUDCA could serve as a novel therapeutic agent in the future management of patients with ALD. Alcohol-related liver disease is a global healthcare concern with limited treatment options. 24-Norursodeoxycholic acid (NorUDCA) is a modified bile acid, which was proven to be effective in human cholestatic liver diseases. In the present study, we found a protective effect of norUDCA in experimental alcoholic liver disease. For patients with ALD, norUDCA could be a potential new treatment option.

Mycoviral gene-incorporating phytopathogenic fungi: a biocontrol agent.

Fungal pathogens cause devastating agroeconomic losses. Chemical fungicides are used to control fungal diseases, although this is not an ecofriendly approach. A recent study by Liu et al. highlighted the use of mycoviral gene-incorporating phytopathogenic fungi as biocontrol agents for disease management.

In vivo antiplasmodial activity and phytochemical composition of Landolphia dulcis (Sabine ex G.Don) Pichon bark and leaf extracts

Landolphia dulcis has been extensively used in folk medicine as sex booster, antidiabetic and antimicrobial especially in Western part of Nigeria. This research aims to investigate the curative potency of L. dulcis leaves and bark in Plasmodium infected mice. The extracts of L. dulcis were investigated against Plasmodiun bergei NK65, a chloroquine sensitive strain using curative assay. Parameters such as percentage inhibition, level of infected red blood cells (parasitaemia), weight variation and packed cell volume were evaluated in experimental mice. The crude extracts were assessed using standard phytochemical methods. The phytochemical screenings of crude extracts revealed the presence of saponins, alkaloids, tannins, phenols, steroids and flavonoids. According to quantitative phytochemical screening, total phenolic, tannins, and flavonoid content were abundant in ethanol (50%) extracts. A significant increase in body weight of extract and chloroquine treated mice was observed; however, a reduction of -3.000 g was evident in group without treatment. A significant increase was observed in packed cell volume of 200 and 400 mg/kg of ethanol (50%) extracts treated groups. An inhibitory activity of 87.7% and 53.61% were observed in 400 mg/kg ethanolic bark extract and 200 mg/kg ethanol (50%) leaves extract respectively, though, inhibitory activity of 100% was observed in chloroquine treated group. The outcomes of this study recommend the use of L. dulcis bark and leaves as a therapeutic agent for management of malaria and as a prospective antimalarial templates. Further studies are needed to investigate the safety and the mechanisms of action of the L. dulcis extracts.

Incretin Analogs for Weight Management in Adults Without Diabetes.

This is a narrative review of incretin analogs and their effect on weight management in adult without diabetes. Randomized controlled trials were identified by English language. PubMed/MEDLINE, Scopus, and Embase databases were searched from inception through June 2023 to identify all pertinent trials reporting outcomes on efficacy and safety search using the terms: tirzepatide, semaglutide, liraglutide, and obesity. Selected studies were included if the study population was composed of adults without diabetes being treated by glucagon-like peptide 1 (GLP-1) receptor agonists or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists for weight management, and weight loss was assessed as a primary outcome. Fifteen studies involving 3 pharmacotherapies (liraglutide, semaglutide, and tirzepatide) were identified. Efficacy data supporting the use of these agents for weight management were promising when compared to placebo and/or other behavioral therapies. Percent weight loss ranged from 5.7% to 11.8%, 14.9% to 17.4%, and 15% to 20.9% for liraglutide, semaglutide, and tirzepatide, respectively. Safety data were relatively similar across all trials and identified gastrointestinal adverse effects as most common. Glucagon-like peptide 1 agonists are preferred for overweight or obese patients by the American Gastroenterological Association. Future guidelines may address tirzepatides' place in therapy as new evidence comes forth. Providers should consider patient-specific factors such as cost, adverse effects, drug interactions, and comorbidities when prescribing these agents and provide education regarding the need for concurrent diet and exercise modifications. All incretin analogs in this review are superior to placebo when used for weight management in adults without diabetes.

Pengaruh Intensitas Persediaan, Leverage dan Kinerja Keuangan Terhadap Penghindaran Pajak

Tax avoidance is based on agency theory, where this theory explains that a company is a form of contract between the owner of the company (principal) and the manager (agent) of the company who takes care of use and control within the company. This study aims to determine the effect of inventory intensity, leverage and financial performance on tax avoidance in LQ-45 index companies for the 2017-2021 period. This type of research is quantitative using secondary data obtained from the Indonesia Stock Exchange (IDX) and the website of each company and the analysis technique used in this study uses multiple linear regression with the help of E-views version 10 software. This research was conducted at companies LQ-45 index. The data sampling technique uses purposive sampling, which are used as research samples are 21 companies with security for 5 years 2017-2021. The results showed that partially leverage and financial performance had no effect on tax evasion while inventory intensity had an effect on tax evasion. While simultaneously inventory intensity, leverage and financial performance have an influence on tax avoidance.

Colonization of Serendipita indica promotes resistance against Spodoptera exigua in onion (Allium cepa L.).

Plant-endophyte symbiosis influences plant defense and growth. Serendipita indica is a root endophyte that promotes growth and induces tolerance against biotic and abiotic stress in plants. In this study, we examined the effect of S. indica colonization on herbivore (Spodoptera exigua) resistance of onion (Allium cepa L.). We found that colonization of S. indica in the roots of onion significantly reduced the feeding damage of leaves by S. exigua larvae, and also resulted in a reduction in weight gain of the larvae when fed on S. indica plants. This enhanced resistance is a result of modulation of antioxidant and defense enzymes/genes in the host by S. indica mutualism. Specifically, the activities of enzymes such as Superoxide dismutase, peroxidase, polyphenol oxidase, phenylalanine ammonia-lyase, and H2O2 content were significantly higher in the early stages of S. exigua feeding in the S. indica colonized plants compared to the non-colonized counterparts. Similarly, defense genes also showed modulation in response to this tripartite interaction of onion -S. indica mutualism and S. exigua herbivory. The hierarchical cluster analysis and principal component analysis indicated a clear difference in the onion biochemical responses, which is due to the S. indica symbiosis. Our investigation demonstrates that onion-S. indica symbiosis significantly decreases chewing injury by efficiently modulating antioxidant and defense enzyme activities and gene expression in response to S. exigua herbivory. Therefore, S. indica can be used as a potential biocontrol agent for sustainable management of this important pest of Alliums.

Agar-agar a promising edible coating agent for management of postharvest diseases and improving banana fruit quality

Agar-agar a promising edible coating agent for management of postharvest diseases and improving banana fruit quality

Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Solid Organ Transplant Recipients.

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) may be effective in reducing body weight and hemoglobin A1c (HbA1c) post-kidney transplantation. Limited literature exists on use of these agents outside of kidney transplant. The purpose of this program evaluation was to evaluate the safety and efficacy of SGLT2i in kidney, liver, and lung transplant recipients. Methods: This was a retrospective program evaluation of adult kidney, liver, and lung transplant recipients between August 31, 2016 and July 31, 2021. Patients initiated on SGLT2i for diabetes for a minimum of 90 days with at least 1 follow-up appointment were screened for inclusion. Outcomes were compared between SGLT2i initiation to nadir values 3-12-months post-initiation. Outcomes included change in hemoglobin A1c, fasting blood glucose, actual body weight, and body mass index. Safety outcomes included adverse effects, cardiovascular events, death-censored graft loss, and all-cause mortality. Results: Forty-nine patients met inclusion criteria, (26 liver, 18 kidney, 4 lung, and 1 simultaneous liver-kidney recipient). The median time from transplant to SGLT2i initiation was 1216 days (IQR 524-2256). Glycemic and weight loss outcomes showed a statistically significant benefit from SGLT2i use. Total safety outcome incidence was minimal at 12 months. No patient experienced myocardial infarctions, graft loss, or mortality at 3-12 months. One incidence of urinary tract infection and stroke occurred each. The most common adverse effects included hypotension and hypoglycemia. Conclusion: This program evaluation demonstrated that SGLT2i can be used safely in solid organ transplant recipients. These agents can provide an additional non-insulin agent for post-transplant diabetes mellitus management in solid organ transplant.

Thrombolytic and anticoagulant efficiencies of purified fibrinolytic enzyme produced from Cochliobolus hawaiiensis under solid-state fermentation.

Cochliobolus hawaiiensis Alcorn Assiut University Mycological Centre 8606 was chosen from the screened 20 fungal species as the potent producer of fibrinolytic enzyme on skimmed-milk agar plates. The greatest enzyme yield was attained when the submerged fermentation (SmF) conditions were optimized, and it was around (39.7U/mg protein). Moreover, upon optimization of fibrinolytic enzyme production under solid-state fermentation (SSF), the maximum productivity of fibrinolytic enzyme was greatly increased recorded a bout (405U/mg protein) on sugarcane bagasse, incubation period of 5 days, moisture level of 100%, initial pH of salt basal medium 7.8, incubation temperature at 35°C, and supplementation of the salt basal medium with corn steep liquor (80％, v/v). The yield of fibrinolytic enzyme by C. hawaiiensis under SSF was higher than that of SmF with about 10.20-fold. The purification procedures of fibrinolytic enzyme by ammonium sulfate (70%), gel filtration, and ion-exchange columns chromatography caused a great increase in its specific activity to 2581.6U/mg protein with an overall yield of 55.89%, 6.37 purification fold and molecular weight of 35kDa. Maximal activity was recorded at pH 7 and 37°C. Significant pH stability was recorded at pH 6.6-7.2, and thermal stability was recorded at 33-41°C. The enzyme showed the highest affinity toward fibrin, with Vmax of 240U/mL and an apparent Km value of 47.61mmol. Mg2+ and Ca2+ moderately induced fibrinolytic activity, whereas Cu2+ and Zn2+ greatly suppressed the enzyme activity. The produced enzyme is categorized as serine protease and non-metalloprotease. The purified fibrinolytic enzyme showed efficient thrombolytic and antiplatelet aggregation activities by completely prevention and dissolution of the blood clot which confirmed by microscopic examination and amelioration of blood coagulation assays. These findings suggested that the produced fibrinolytic enzyme is a promising agent in management of blood coagulation disorders.

Virtual Care? Telepharmacy in Critical Care Settings for Patient-Centered Care and Multidisciplinary Collaboration: A Scoping Review of Activities, Benefits, Economic Impact, Challenges, and Knowledge Gaps.

Background: Very few studies have investigated telepharmacy (TP) in critical care. This scoping review undertook this task. Methods: We searched the following five electronic databases (PubMed, Embase, WoS, Scopus, CINAHL). Data were extracted from the articles and mapped out. Arksey and O'Malley's 6-step framework was used, and data synthesis identified activities, benefits, economic impact, challenges, and knowledge gaps of TP in critical care. Results: Out of 77 reports retrieved, 14 were included in the review as per inclusion criteria. Eight studies (57%) were published since 2020, and 9 (64%) were from the United States. Tele-ICU was in place before TP implementation in six studies (43%). TP used a range of synchronous/asynchronous communications. Studies reported wide assortment of reactive/scheduled TP activities. Patient outcomes were evaluated in one study of sedation-related TP interventions but they were not different despite improved compliance with sedation protocol. Most common clinical interventions/drugs included glycemic, electrolyte, and antimicrobial therapy management and antithrombotic agents among others. Acceptance of TP interventions was 75% or more in four studies and 51-55% in two studies. Benefits of TP included resolved drug-related problems, increased compliance with guidelines, maintained interactions with other health care providers, and patient safety among others. Three studies (21%) reported cost avoidance with TP interventions. Challenges included communication, intervention documentation, tracking implementation of recommendations, and monetary/financial and legislative/regulatory issues. Knowledge gaps comprised lack of frameworks for implementation/evaluation of TP in critical care, methodological aspects, lack of patient-specific outcomes, as well as institution/health-system aspects, and documentation systems, cost, legislative, and sustainability issues. Conclusions: TP in critical care is underpublished, and comprehensive frameworks for its implementation and evaluation remain lacking. Assessments are needed to evaluate the effect of TP in critical care on patient-specific outcomes, its economic and legal dimensions, methods to sustain it, as well as the role of documentation systems, collaboration models, and institutional characteristics.

Prescription pain medications for disorders of gut-brain interaction: Comparing usage patterns with clinical practice recommendations.

Treatment of gastrointestinal pain remains a significant challenge in the management of many disorders of gut-brain interaction (DGBI). Pharmacologic agents and various behavioral therapies are among the potential therapeutic options for pain-predominant DGBI such as irritable bowel syndrome, functional dyspepsia, functional heartburn, and centrally mediated abdominal pain syndrome. In the retrospective study published in this journal, Luo et al. examine the use of prescription pain medications from a global perspective among patients with DGBI using the Rome Foundation Global Epidemiology Study. This review article provides an overview of usage patterns of various pharmacologic pain management agents (opioids, central neuromodulators, antispasmodics, and other peripherally acting agents) and non-pharmacologic therapies in the context of clinical practice recommendations on the management of DGBI pain.

An Insilico Computational Screening of Siddha Formulation Kalingathy Thailam against Cyp- 17α-Hydroxylase in PCOS

Background: PCOS is characterized by ovulatory failure, hirsutism, obesity, glucose intolerance, resistance to insulin, dyslipidemia and infertility. Siddha system of medicine has a worthwhile therapeutic effect in treating PCOS. The bioactive compounds of Kalingathy Thailam mentioned in Siddha literature was selected for evaluating their ability to inhibit CYP- 17α-hydroxylase. Objective: The study is aimed to perform the In Silico computational screening of the formulation Kalingathy Thailam against the target enzyme CYP-17 α -hydroxylase in PCOS. Methods: Autodock program was used against the target enzyme CYP-17 α -hydroxylase for the phytocomponents such as Sinapic acid, Cucurbitacin B of Citrullus colocynthis (L. ) Schrader, Aromadendrene, Linolenic acid of Melia dubia Linn. , Onionin A, Protocatechuic acid of Allium cepa Linn. , Ascorbic acid, Limonene of Citrus limon (L. )Burm. f. , Ricinine of Ricinus communis Linn. Results: A total of 9 components were screened, out of these Protocatechuic acid, Ascorbic acid, Linolenic acid and Cucurbitacin B reveals maximum of 2 to 3 interactions accounting for 75-100% binding efficacy with the core active amino acid residues present on the target enzyme CYP- 17α-hydroxylase. Conclusion: Based on the results of the computational analysis it was concluded that the bio-active compounds present in the herbal ingredients possess significant binding against the target enzyme CYP-17α-hydroxylase by interacting with active amino acids. Hence these phytocomponents which inhibit the target enzyme may act as a potential therapeutic agent for management of PCOD.

Assigning cause for emerging diseases of aquatic organisms.

Resolving the cause of disease (= aetiology) in aquatic organisms is a challenging but essential goal, heightened by increasing disease prevalence in a changing climate and an interconnected world of anthropogenic pathogen spread. Emerging diseases play important roles in evolutionary ecology, wildlife conservation, the seafood industry, recreation, cultural practices, and human health. As we emerge from a global pandemic of zoonotic origin, we must focus on timely diagnosis to confirm aetiology and enable response to diseases in aquatic ecosystems. Those systems' resilience, and our own sustainable use of seafood, depend on it. Synchronising traditional and recent advances in microbiology that span ecological, veterinary, and medical fields will enable definitive assignment of risk factors and causal agents for better biosecurity management and healthier aquatic ecosystems.

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus.

Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is characterized by extreme heterogeneity with a variable clinical course. Renal involvement may be observed and affects the outcome. Hydroxychloroquine should be administered to every lupus patient irrespective of organ involvement. Conventional immunosuppressive therapy includes corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporine and tacrolimus. However, despite conventional immunosuppressive treatment, flares occur and broad immunosuppression is accompanied by multiple side effects. Flare occurrence, target organ involvement, side effects of broad immunosuppression and increased knowledge of the pathogenetic mechanisms involved in SLE pathogenesis as well as the availability of biologic agents has led to the application of biologic agents in SLE management. Biologic agents targeting various pathogenetic paths have been applied. B cell targeting agents have been used successfully. Belimumab, a B cell targeting agent, has been approved for the treatment of SLE. Rituximab, an anti-CD20 targeting agent is also used in SLE. Anifrolumab, an interferon I receptor-targeting agent has beneficial effects on SLE. In conclusion, biologic treatment is applied in SLE and should be further evaluated with the aim of a good treatment response and a significant improvement in quality of life.

Ticagrelor washout bridged with GPIIb/IIIa inhibitor infusion to facilitate surgical care following placement of pipeline flow diverters: a case report

Background: Pipeline flow diverters (PFDs) are becoming increasingly common. Antiplatelet medication is required to minimize periprocedural ischemic events. Short-acting GPIIb/IIIa inhibitors are frequently administered intraprocedurally; however, the role of these agents in postprocedural PFD management in the neurocritical care unit (NCCU) has been overlooked.Case Report: A patient with an unruptured internal carotid artery aneurysm presented for PFD placement. PFD placement was complicated by post-procedure intra-PFD thrombosis and hemispheric ischemia. Aspirin and ticagrelor were restarted, and the surgery department consulted for tracheostomy and percutaneous endoscopic gastrostomy-tube placement. Short-half-life GPIIb/IIIa infusions served as bridges to surgery after aspirin and tirofiban washout.Conclusion: NCCU management of complications of PFD placement remains under-researched. The use of long-acting antiplatelet agents post-PFD limits the safe administration of surgical procedures. Bridging with GPIIb/IIIa infusion may facilitate the safe delivery of intensive care in these cases.

Biliary Ascariasis with Gallbladder Invasion: A Unique Entity

ntestinal Ascariasis is a common helminthic infection in developing countries and in some rare cases, worms migrate to the biliary tract and gall bladder. Extraintestinal biliary ascariasis presents with jaundice, right upper quadrant abdominal pain, and vomiting. Ultrasonography is a useful diagnostic modality. Albendazole and Mebendazole are commonly used anti-helmintic agents for conservative management, whereas endoscopic removal is needed in rare cases.

Alpinumisoflavone Activates Disruption of Calcium Homeostasis, Mitochondria and Autophagosome to Suppress Development of Endometriosis.

Alpinumisoflavone is an isoflavonoid extracted from the Cudrania tricuspidate fruit and Genista pichisermolliana. It has various physiological functions, such as anti-inflammation, anti-proliferation, and apoptosis, in malignant tumors. However, the effect of alpinumisoflavone is still not known in chronic diseases and other benign reproductive diseases, such as endometriosis. In this study, we examined the cell death effects of alpinumisoflavone on the endometriosis cell lines, End1/E6E7 and VK2/E6E7. Results indicated that alpinumisoflavone inhibited cell migration and proliferation and led to cell cycle arrest, depolarization of mitochondria membrane potential, apoptosis, and disruption of calcium homeostasis in the endometriosis cell lines. However, the cellular proliferation of normal uterine epithelial cells was not changed by alpinumisoflavone. The alteration in Ca2+ levels was estimated in fluo-4 AM-stained End1/E6E7 and VK2/E6E7 cells after alpinumisoflavone treatment with or without calcium inhibitor, 2-aminoethoxydiphenyl borate (2-APB). The results indicated that a combination of alpinumisoflavone and a calcium inhibitor reduced the calcium accumulation in the cytosol of endometriosis cells. Additionally, alpinumisoflavone decreased oxidative phosphorylation (OXPHOS) in the endometriotic cells. Moreover, protein expression analysis revealed that alpinumisoflavone inactivated AKT signaling pathways, whereas it increased MAPK, ER stress, and autophagy regulatory proteins in End1/E6E7 and VK2/E6E7 cell lines. In summary, our results suggested that alpinumisoflavone could be a promising effective management agent or an adjuvant therapy for benign disease endometriosis.

Effect of Biosynthesized Nanoselenium on Controlling Tomato Root-Knot Nematode Meloidogyne incognita

Tomato is a globally important fruit crop, which is easily susceptible to infection by plant-parasitic nematodes during growth. In this study, selenium nanoparticles were biosynthesized through the selenite reduction pathway in a wild-type Pseudomonas stutzeri BB19 and were characterized by uniform nanostructured needle-like forms with an average size of 95.2 nm. The nematicidal effect of biosynthesized selenium nanoparticles (BioSeNPs) at different concentrations (2, 6, and 10 ppm) during the pre- or post-infection of tomato root-knot nematode (RKN), Meloidogyne incognita, was assessed under greenhouse conditions. The BioSeNPs were applied as a foliar spray or a soil drench, compared to ethoprophos nematicide (100 mL/pot). The results showed that the ethoprophos nematicide significantly reduced the number of galls, egg mass, and eggs/egg mass of M. incognita by 94.2, 92.8, and 49.8%, respectively. BioSeNPs, as foliar sprays, significantly reduced the number of galls in post-treated infected tomato plants at 10 ppm and in pre-treated infected tomato plants at 2 ppm by 91.9 and 91.4%, respectively. Concerning the egg mass, BioSeNPs significantly reduced it in pre-treated infected tomato plants at 2 ppm as a foliar spray by 90.9%. Moreover, BioSeNPs significantly reduced the eggs/egg mass in pre-treated infected tomato plants at 2 ppm as a soil drench by 43.3%. On the other hand, the BioSeNPs considerably improved tomato growth, chlorophyll a and b, carotenoid content, and enzymes (i.e., catalase and peroxidase) activity compared to untreated infected tomato plants (negative control). Hence, the BioSeNPs show a significant application potential as a cost-effective and environmentally friendly biocontrol agent for RKN management in tomato plants.